Inventiva (IVA) Stock Forecast, Price Target & Predictions
IVA Stock Forecast
Inventiva stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IVA Analyst Ratings
According to 2 Wall Street analysts, Inventiva's rating consensus is 'Buy'. The analyst rating breakdown for IVA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 20, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Apr 08, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| May 19, 2023 | Societe Generale | - | Buy | Upgrade |
Inventiva's last stock rating was published by Canaccord Genuity on May 20, 2024. The company gave IVA a "Buy" rating, the same as its previous rate.
Inventiva Financial Forecast
Inventiva Revenue Forecast
| Jun 27 | Mar 27 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $50.04M | $46.24M | $14.35M | $1.15M | $4.54M | $3.77M | $3.59M | $1.24M | $17.90M | $1.37M | $1.38M |
| High Forecast | $50.04M | $46.24M | $14.35M | $1.15M | $4.54M | $3.77M | $3.59M | $1.24M | $17.90M | $1.37M | $1.38M |
| Low Forecast | $50.04M | $46.24M | $14.35M | $1.15M | $4.54M | $3.77M | $3.59M | $1.24M | $17.90M | $1.37M | $1.38M |
| # Analysts | - | - | - | - | - | - | - | 1 | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Inventiva's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IVA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Inventiva EBITDA Forecast
| Jun 27 | Mar 27 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-50.04M | $-46.24M | $-14.35M | $-1.15M | $-4.54M | $-3.77M | $-3.59M | $-1.24M | $-17.90M | $-1.37M | $-1.38M |
| High Forecast | $-50.04M | $-46.24M | $-14.35M | $-1.15M | $-4.54M | $-3.77M | $-3.59M | $-1.24M | $-17.90M | $-1.37M | $-1.38M |
| Low Forecast | $-50.04M | $-46.24M | $-14.35M | $-1.15M | $-4.54M | $-3.77M | $-3.59M | $-1.24M | $-17.90M | $-1.37M | $-1.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict IVA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inventiva's previous annual EBITDA (undefined) of $NaN.
Inventiva Net Income Forecast
| Jun 27 | Mar 27 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-39.54M | $-58.83M | $-25.26M | $-40.21M | $-36.48M | $-30.64M | $-49.92M | $-36.55M | $70.63M | $-17.84M | $-22.70M |
| High Forecast | $-39.54M | $-58.83M | $-25.26M | $-40.21M | $-36.48M | $-30.64M | $-49.92M | $-36.55M | $70.63M | $-17.84M | $-22.70M |
| Low Forecast | $-39.54M | $-58.83M | $-25.26M | $-40.21M | $-36.48M | $-30.64M | $-49.92M | $-36.55M | $70.63M | $-17.84M | $-22.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Inventiva's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IVA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Inventiva SG&A Forecast
| Jun 27 | Mar 27 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $299.43M | $276.67M | $85.85M | $6.89M | $27.18M | $22.57M | $21.49M | $7.45M | $107.12M | $8.22M | $8.28M |
| High Forecast | $299.43M | $276.67M | $85.85M | $6.89M | $27.18M | $22.57M | $21.49M | $7.45M | $107.12M | $8.22M | $8.28M |
| Low Forecast | $299.43M | $276.67M | $85.85M | $6.89M | $27.18M | $22.57M | $21.49M | $7.45M | $107.12M | $8.22M | $8.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Inventiva's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IVA last annual SG&A of $NaN (undefined).
Inventiva EPS Forecast
| Jun 27 | Mar 27 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.81 | $-1.21 | $-0.52 | $-0.83 | $-0.75 | $-0.63 | $-1.03 | $-0.75 | $1.45 | $-0.37 | $-0.46 |
| High Forecast | $-0.81 | $-1.21 | $-0.52 | $-0.83 | $-0.75 | $-0.63 | $-1.03 | $-0.75 | $1.45 | $-0.37 | $-0.46 |
| Low Forecast | $-0.81 | $-1.21 | $-0.52 | $-0.83 | $-0.75 | $-0.63 | $-1.03 | $-0.75 | $1.45 | $-0.37 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Inventiva's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IVA previous annual EPS of $NaN (undefined).
Inventiva Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.20 | $36.00 | 1536.36% | Buy |
| VTYX | Ventyx Biosciences | $2.17 | $33.86 | 1460.37% | Buy |
| VRCA | Verrica Pharmaceuticals | $1.91 | $12.00 | 528.27% | Buy |
| IPHA | Innate Pharma | $2.31 | $10.00 | 332.90% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| VIGL | Vigil Neuroscience | $3.42 | $11.00 | 221.64% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| IMCR | Immunocore | $33.40 | $78.17 | 134.04% | Buy |
| NAMS | NewAmsterdam Pharma Company | $16.40 | $36.00 | 119.51% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| JANX | Janux Therapeutics | $41.26 | $59.25 | 43.60% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| PCVX | Vaxcyte | $111.58 | $117.00 | 4.86% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
IVA Forecast FAQ
Is Inventiva a good buy?
Yes, according to 2 Wall Street analysts, Inventiva (IVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IVA's total ratings.
What are Inventiva's analysts' financial forecasts?
IVA's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $2.76M (high $2.76M, low $2.76M), average EBITDA is $-2.758M (high $-2.758M, low $-2.758M), average net income is $-40.533M (high $-40.533M, low $-40.533M), average SG&A $16.5M (high $16.5M, low $16.5M), and average EPS is $-0.828 (high $-0.828, low $-0.828).